| 2021 | A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2017 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors | INVESTIGATIONAL NEW DRUGS |
| 2010 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer | INVESTIGATIONAL NEW DRUGS |
| 2012 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2013 | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas | INVESTIGATIONAL NEW DRUGS |
| 2012 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2014 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2012 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer | INVESTIGATIONAL NEW DRUGS |
| 2020 | A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy | INVESTIGATIONAL NEW DRUGS |
| 2013 | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer | INVESTIGATIONAL NEW DRUGS |
| 2013 | Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent | INVESTIGATIONAL NEW DRUGS |
| 2014 | Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial | INVESTIGATIONAL NEW DRUGS |
| 2022 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2013 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide | INVESTIGATIONAL NEW DRUGS |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
| 2011 | Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2021 | Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea | INVESTIGATIONAL NEW DRUGS |
| 2011 | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial | INVESTIGATIONAL NEW DRUGS |
| 2012 | Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. | INVESTIGATIONAL NEW DRUGS |
